About the Center | Find A Doctor | Contact Us |
 


  Home
    

  Information by Cancer Type
    

  Services and Treatment
    

  Clinical Outcomes
    

  Cancer Supportive Services
    

  Find A Doctor
    

  Clinical Trials
    

  Leadership
    

  Make a Donation
    

  Contact Us
    
.
Clinical Outcomes

For information about current clinical trials, please click here.

Back to Outcomes

Diffuse Large B-Cell NHL Lymphoma

Overall survival for all patients under age 80 with stage I or stage II diffuse large B-cell NHL who are HIV negative treated at CCCNY (Mount Sinai Beth Israel-Petrie and Mount Sinai Beth Israel Brooklyn, and Mount Sinai St. Luke's Roosevelt). Patients received R-CHOP or CHOP-like regimens with or without radiation therapy. Our data exclude patients with very early deaths, less than 30 days after diagnosis, since many of these patients had significant co-morbid disease that led to early death or could not receive adequate therapy. It is unusual for a patient with early stage DLBCL to die related to disease or therapy within 30 days of diagnosis. The reported five-year overall survival for stage I/II DLBCL patients treated on cooperative group clinical trials is 70%-90%. Our results include some patients who would likely have been excluded from trials because of their poor condition. The five-year survival at CCCNY is 68%.

Overall survival for all patients under age 80 with stage III or stage IV diffuse large B-cell NHL who are HIV negative treated at CCCNY (Mount Sinai Beth Israel-Petrie and Mount Sinai Beth Israel Brooklyn, and Mount Sinai St. Luke's Roosevelt). Patients received therapy with R-CHOP or CHOP-like regimens or were treated on clinical trials. Our data exclude patients with very early deaths, less than 30 days after diagnosis, since many of these patients had significant comorbid disease that led to early death or could not receive adequate therapy. The reported five- year overall survival for stage III/IV patients treated on cooperative group clinical trials is 40%-60%. Our results include some patients who would likely have been excluded from trials because of their poor condition. Despite this, our results are similar to results from trials. Our patientsí five-year survival is 53%. Our data do not include international prognostic indicators for all patients, so we cannot exclude that our favorable outcomes as compared with national data could reflect a favorable prognostic profile for our patients.


.
 
Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System